




IPO STATISTICS

IPO Price (RM)	Retail price: 0.33 Institutional price to be determined by bookbuilding
Fund Raised (RM million) <i>Based on retail price of RM0.33</i>	72.2 from new issue
Enlarged issued share capital upon listing (million shares)	818.8
IPO Market Capitalisation (RM million) <i>Based on retail price of RM0.33</i>	270.2
Price Earnings Ratio (PER)	27.01x

Use of Proceeds (RM72.2 million from new issue)



BUSINESS OVERVIEW

Business Activities

Cengild Medical Berhad is a healthcare service provider operating a medical centre at Nexus @ Bangsar South, Kuala Lumpur. It specialises in the diagnosis and treatment of gastrointestinal and liver diseases, and obesity.

The medical centre has 10 clinics, three endoscopy rooms, 28 beds, two operating theatres, radiology department, accident and emergency department, pharmacy, laboratory, and central sterile supply department. It has six employee consultants, five resident consultants, 17 visiting consultants and four medical officers.

Cengild's business activities comprise the following:

- Consultant services on gastrointestinal and liver diseases
- Medical management services supporting consultant services with facilities available at its medical centre to provide care and comprehensive medical treatments for its patients.
 - Nursing services - provision of care to patients when admitted to medical centre; assist consultants during various medical procedures
 - Clinical support services - complement and support consultants, including pharmacy, maintain medical records, dietitian, physiotherapy, laboratory testing, special diagnostics, and radiology.

Competitive Strength

- Unique value proposition as the only independent full-fledged medical centre in Malaysia specialising in gastrointestinal and liver diseases, and obesity. Specialisation within a single discipline enables the medical centre to be cost effective and to provide in-depth and more targeted diagnostic services and treatments, and to undertake complex procedures and surgeries related to gastroenterology and liver diseases, and obesity.
- Reputable and experienced team of consultants supported by nursing staff and clinical support staff
- Modern equipment and facilities
- Wide range of insurance and corporate panels
- Provision of complementary healthcare services that support core specialties, such as urology, oncology, cardiology, and gynaecology, as well as comprehensive on-site laboratory services, 24-hour accident and emergency services, health screening, physiotherapy, dietetic and inpatient




New Patients

FY2019: 4,198 | FY2020: 4,693 | FY2021: 6,258

GROWTH STRATEGIES AND FUTURE PLANS

- **Expansion of existing medical centre:** leasing new space to cater to current and future demand for its medical services, especially endoscopic procedures; renovation and purchase necessary medical furniture, devices, and equipment
- **Geographical expansion:** establishing two new medical centres in other major cities in Malaysia
- **Expansion of medical team:** attracting and recruiting consultants and surgeons in the areas of gastroenterology and hepatology

FINANCIAL PERFORMANCE & PEER ANALYSIS



Peer Analysis

Company	PAT Margin (%)	PER (x)
IHH Healthcare Berhad	11.4	32.57
KPJ Healthcare Berhad	7.5	91.48
TMC Life Sciences Berhad	10.0	49.45
Optimax Holdings Berhad	13.8	25.75
Cengild Medical Berhad	15.8	27.01

* Selected peers listed on Bursa Malaysia as identified in Section 4.5.1 of the prospectus. KPJ Healthcare Berhad is deemed as an outlier due to extreme standard deviation from the mean. PAT margin based on prospectus and company announcements. Trailing 12 month PER data from prospectus, Cengild's PER at IPO.

PROMOTERS & SUBSTANTIAL SHAREHOLDERS

Promoter/ Substantial Shareholder	Designation	Shareholding after IPO	
		Direct	Indirect
Dato' Dr Tan Huck Joo	Promoter and Substantial Shareholder. Executive Chairman	16.67%	-
Emeritus Professor Dato' Dr Goh Khean Lee	Promoter and Substantial Shareholder. Executive Director	7.35	-
Dr Mohamed Akhtar Bin Mohamed Ditali Qureshi	Promoter and Substantial Shareholder. Executive Director	7.01	-
Anne Marie Loh Foong Han	Promoter and Substantial Shareholder	9.81	-
Dr Ramesh A/L Gurunathan	Promoter. Head of Department, Inpatient	4.86	-
Dr Ong Siew Kuen	Promoter. Head of Department, Medicine	3.41	-

DISCLAIMER: This report is provided for general information purposes only. Although care has been taken to ensure the accuracy of the information within this report, Bursa Malaysia Berhad and its subsidiaries (“Bursa Malaysia Group”) do not warrant or represent, expressly or impliedly as to the completeness, accuracy or currency of the information in this report. Bursa Malaysia Group does not endorse and shall not be liable for any information in this report that have been obtained via third party sources (if any).

The information contained in this report is neither an offer or solicitation to enter into any transaction nor is it a recommendation or endorsement of any product(s) mentioned in this report. The information also does not constitute legal, financial, trading or investment advice. You are advised to seek independent advice and/or consult relevant laws, regulations and rules prior to trading/investing. Bursa Malaysia Group does not accept any liability howsoever arising, including any liability arising from any trading/investment decisions made on the basis of this information.

This report or any part of this report shall not be used or reproduced in any form without Bursa Malaysia Berhad’s prior written